GLP-1 + amylin fat loss blend (Cagrilintide / Semaglutide)
GLP-1 plus amylin — the pairing behind the strongest fat loss data of the decade.

CagriSema pairs Semaglutide (a GLP-1 receptor agonist) with Cagrilintide (a long acting amylin analog). Amylin hits satiety pathways GLP-1 misses, which is why in trials this combo produced meaningfully greater weight loss than either alone — with less appetite rebound between doses.
Titrate up slowly — combined GI side effects can be additive in the first 2–3 weeks.
Educational only · Not a vendor claim
Semaglutide activates GLP-1 receptors (satiety, gastric emptying, insulin). Cagrilintide is a long acting amylin analog that hits satiety and glucose control through a separate pathway. Together they cover appetite regulation more completely than either alone.
Educational summary · Not medical advice · Discuss with a qualified clinician
General pattern for the Fat Loss category. Individual response varies.
Reminder: 100 units on an insulin syringe = 1 mL. Always start at half the listed dose for the first week and rotate injection sites between arms, legs, abdomen, and glutes.
Sign in to keep a private log of your doses and notes for CagriSema Blend.
Use code ANYPEPTIDES15 for 15% off your order.
Discount may end or change without notice.